Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2672361 | 0.85 | TAAR1 (0.51) | ALDH1A1 | |
| SCHEMBL11261335 | 0.85 | LDHA (0.49) | ALDH1A1 | |
| SCHEMBL11264972 | 0.85 | ALDH1A1 (0.42) | ALDH1A1 | |
| SCHEMBL11270978 | 0.82 | HDAC1 (0.44) | HDAC1TSHRCHRM3 | |
| SCHEMBL11261128 | 0.81 | MAPT (0.46) | ALDH1A1 | |
| SCHEMBL7640217 | 0.81 | MTNR1A (0.53) | MTNR1AMTNR1BL3MBTL1ALDH1A1MAPK1 | |
| SCHEMBL11261409 | 0.80 | MAPT (0.45) | — | |
| SCHEMBL11261630 | 0.80 | MAPT (0.45) | — | |
| SCHEMBL11263275 | 0.80 | MAPT (0.45) | — | |
| SCHEMBL2178506 | 0.80 | MAPK1 (0.70) | MTNR1AMTNR1BL3MBTL1ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6566385-B2 | And the prenylation of the oncogene protein Ras; peptidomimetic macrocyclic compounds | MERCK & CO., INC. | 2003-05-20 | — | — | US | disclosed |
| US-20020099007-A1 | Inhibitors of prenyl-protein transferase | MERCK SHARP & DOHME CORP. | 2002-07-25 | — | — | US | disclosed |
| WO-2001051127-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2001-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099007-A1 | Inhibitors of prenyl-protein transferase | FNTA, KRAS, NRAS | MTNR1A 4234/4885MTNR1B 4277/4885L3MBTL1 1868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.